Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... forma net operating loss of $1.3 million for the second quarter compared to pro forma net operating ... amortizing the license fee into revenue in the second quarter. Isis received a $375,000 ... Net loss from continuing operations for the second quarter of 2009 was $3.8 million compared to net ...Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for ... loss of $33.4 million or $0.36 per share in the second quarter of 2008. Nektar made ... expenses were down 19% to $43.5 million in the second quarter of 2009 as compared to $53.8 million in ...Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference
... risk of dementia associated with PTSD. A second study suggests lower Alzheimer's risk among ... and had the fastest rate of decline. A second study in post-menopausal women found that ... participants for clinical studies is the second greatest barrier to developing better treatments ...Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
... Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug ... treatment has the potential to impact the second phase of HCV virus inhibitory kinetics in ... postulated to have the greatest impact on HCV second phase inhibition, leading us to evaluate CTS-1027 ...Gene Findings Unlocking Reasons for Neuroblastoma Risk
... to a high-risk form of neuroblastoma. A second genome-wide study found that a copy number ... or early childhood development. Maris's second study, spearheaded by Dr. Sharon Diskin, also of ... is among the largest in the country, ranking second in National Institutes of Health funding. In ...CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
... progression free rate supports advancement into second stage of Simon 2-Stage designed trial - ... met the efficacy criteria for advancement to the second stage of enrollment. To date, 29 patients have ... the Phase II trial will now advance to the second stage and enroll a total of approximately 25 ...Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
... Plans Jazz Pharmaceuticals has completed its second Phase III clinical trial of JZP-6 and expects to ... mid-2009. Assuming positive results for the second study, the company anticipates submitting a New ... including the timing of results from the second Phase III pivotal clinical trial and the ...Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
... Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the ... when used alone, and now we have evidence from a second study that Clonicel also has a complementary ... current study of 200 children with ADHD is the second phase 3 trial in a year to investigate the safety ...Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
... upcoming EASL meeting. Pharmasset's unpartnered second generation HCV nucleoside, PSI-7851, is ... expect to report the first antiviral data in the second half of 2009. In addition, we are collecting ... Phase 2 clinical trial. PSI-7851, an unpartnered second generation HCV nucleotide analogue recently ...Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
... regimen that helps to prolong life." The second component of the trial will examine the safety of ... been approved to improve lung hydration. A second Phase III clinical trial is actively recruiting ... Argentina, Germany, Belgium and France. This second trial has been designed with the assistance of ...Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
... study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor ... for Pharmasset. PSI-7851 is a wholly owned, second generation nucleotide analog that was discovered ... the first antiviral data with PSI-7851 in the second half of 2009." About PSI-7851 PSI-7851 ...Pharmasset Reports Fiscal Year End 2008 Financial Results
... 2008, Pharmasset nominated PSI-7851 as its lead, second generation nucleotide candidate for HCV. ... 2009 -- Report phase 1 data with PSI-7851 in second half of 2009 About Pharmasset ... Pharmasset also anticipates filing an IND for its second generation nucleotide inhibitor for HCV, PSI-7851 ...Brain Waves Show Sound Processing Abnormalities in Autistic Children
... Dr. Roberts said. "We see a fraction of a second delay in autistic patients." Autism is a ... children with autism there was a fraction of a second delay in the brain's response while processing ... processing system is delayed a fraction of a second in children with autism. Autism ...U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
... all four serotypes of dengue one month after the second injection (Day 56), and were highly protected ... all four serotypes of dengue one month after the second injection (Day 56), and were partially protected ... often occurs in children infected for a second time (with a different serotype of dengue), and ...Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
... trial, expected by mid-2009 - - Data from second Phase 3 trial, BLISS-76, expected by fall 2009 - ... enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials ... Phase 3 trial by mid-2009, and data from our second Phase 3 trial by fall 2009. Assuming positive ...Cardium Reports on Second Quarter 2008 Highlights and Financial Results
... as well as financial results for its second quarter ended June 30, 2008. (Logo: ... depreciation and amortization for the second quarter of fiscal 2008 totaled $943,000. Total revenue for the second quarter 2008 was $627,000, compared to $229,000 ...Amicus Therapeutics Announces Second Quarter 2008 Financial Results
... today announced financial results for the second quarter of 2008. On a reported basis calculated ... securities totaled $145.0 million. "The second quarter of 2008 was significant for Amicus. We ... President and CEO of Amicus Therapeutics. "In the second half of 2008, we will be focused on finalizing ...Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
... trial, and have initiated dosing of our second AZ-004 Phase 3 clinical trial. In addition, we ... this trial before the end of September 2008. A second Phase 3 clinical trial was initiated in July 2008 ... an end of Phase 2 meeting with the FDA during the second quarter of 2008 and has been granted this meeting ...Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
... plan to initiate by the end of this year, and the second late-stage study of mipomersen, a ... for this indication is anticipated during the second half of 2010. Genzyme and Isis plan to begin ... LDL cholesterol in high-risk patients during the second half of 2008. These trials will include: one ...CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
... today reported its financial results for the second quarter of 2008 and updated clinical progress of ... Significant one time transactions during the second quarter of 2008 included the sale of the rights ... and investments to fund operations during the second half of 2008. The Company expects to end 2008 ...Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
... ALXA ) announced today that it has initiated its second Phase 3 clinical trial with AZ-004 (Staccato(R) ... our AZ-004 NDA plan with the start of the second Phase 3 clinical trial this year. We look forward ... sales and marketing of AZ-004." AZ-004 second Phase 3 Clinical Trial Design ...AFFiRiS: Milestone Reached in Clinical Trial of Alzheimer's Vaccine
... already begun for the clinical trial of a second Alzheimer's vaccine by AFFiRiS. Vienna-based ... to offer participation in clinical testing of our second Alzheimer's vaccine, AFFITOPE AD02. The support ... treatment, Alzheimer's is one such disease. The second disease that AFFiRiS has chosen to tackle ...